Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES). // JAAD International. – URL: https://www.sciencedirect.com/science/article/pii/S3117504X26000641?dgcid=rss_sd_all
Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES). JAAD International. https://www.sciencedirect.com/science/article/pii/S3117504X26000641?dgcid=rss_sd_all
“Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES).” JAAD International.
@article{article5799,
title = {Phase II study of brigatinib for ALK-positive advanced non-small cell lung cancer with untreated brain metastases (LOGIK2201: BRAVES)},
journal = {JAAD International},
url = {https://www.sciencedirect.com/science/article/pii/S3117504X26000641?dgcid=rss_sd_all}
}